Tradestie Institutional Equity Comparison Engine

IONS vs KYMR โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

KYMR Overall Edge

KYMR Captures Institutional Edge (3โ€“1 Pillars ยท 6โ€“4 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Kymera Therapeutics, Inc. Common Stock (KYMR) driven by superior Growth & Margin, Momentum & Technical, Options & Structure while IONS counters with relative strength in Valuation. Fundamentally, IONS trades at 90.9x Forward P/E with -58.8% operating margin (+54.9% YoY revenue) versus KYMR at N/M Forward P/E and -396.0% operating margin (+466.4% YoY). In options structure, IONS sits in BREAKDOWN (17th %ile IV; Dealer Gamma Walls on Pro) against KYMR sits in CONSOLIDATION (23rd %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner IONS
IONS 90.9x vs KYMR N/M Fwd P/E
Growth & Margin Winner KYMR
Op Margin -58.8% vs -396.0% ยท YoY +54.9% vs +466.4%
Momentum & Technical Winner KYMR
1Y -59.1% vs +96.1% ยท 52W Pos 2% vs 78%
Options & Structure Winner KYMR
BREAKDOWN (17th %ile IV) vs CONSOLIDATION (23rd %ile IV)
IONS NASDAQ
Ionis Pharmaceuticals, Inc. Common Stock
Pharmaceutical Preparations
$28.57
-1.7% 1D
Market Cap $4.7B
1M Return -33.48%
1Y Return -59.1%
Forward P/E 90.9x
Unified AI Score
63.9 / 100 BUY
Tech 60.0 Fund 63.0 Flow 73.0 Mom 55.0
KYMR NASDAQ
Kymera Therapeutics, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$124.79
-2.18% 1D
Market Cap $10.9B
1M Return +19.1%
1Y Return +96.12%
Forward P/E N/M
Unified AI Score
47.1 / 100 HOLD
Tech 36.0 Fund 50.0 Flow 67.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: IONS -59.1% KYMR +96.12% Spread: +155.22 pp (KYMR Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period IONS Revenue KYMR Revenue IONS Op. Margin KYMR Op. Margin Margin Edge
FY2018 $600M N/A -10.2% N/A IONS
FY2019 $1.12B $0M 32.6% -1438.5% IONS
FY2020 $730M $30M -23.6% -136.1% IONS
FY2021 $810M $70M -3.7% -138.0% IONS
FY2022 $590M $50M -69.8% -344.4% IONS
FY2023 $790M $80M -44.9% -210.6% IONS
FY2024 $710M $50M -67.4% -555.8% IONS
FY2025 $940M $40M -40.4% -891.1% IONS

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: IONS (4) vs KYMR (6)
Institutional Metric IONS KYMR Criterion Row Winner
Market Capitalization Scale $4.7B $10.9B Larger Scale KYMR
Trailing P/E Ratio Valuation 90.9x N/M Lower Multiple IONS
Forward P/E Ratio Valuation 90.9x N/M Lower Multiple IONS
Revenue Growth (YoY) Growth +54.9% +466.4% Higher Growth KYMR
Operating Margin (TTM) Profitability -58.8% -396.0% Higher Margin IONS
Net Profit Margin Profitability -56.9% 0.0% Higher Margin KYMR
Return on Equity (ROE) Capital Efficiency -108.0% -27.3% Higher ROE KYMR
52-Week Range Position Momentum 2% ($27โ€“$87) 78% ($62โ€“$143) Stronger Trend KYMR
Beta / 30D Volatility Risk Regime 0.18ฮฒ ยท 86% Vol 1.04ฮฒ ยท 54% Vol Lower Realized Risk KYMR
Unified Institutional Score Composite Signal 63.9 / 100 (BUY) 47.1 / 100 (HOLD) Higher Composite IONS

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full IONS vs KYMR Buy Guide
IONS BREAKDOWN
58d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 17th %ile
IV Regime Compressed (<25th %ile)
Live IONS Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
KYMR CONSOLIDATION
62d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 23rd %ile
IV Regime Compressed (<25th %ile)
Live KYMR Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither IONS nor KYMR registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.